Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca reported Q1 2026 Total Revenue of $15.3 billion, up 8% at constant exchange rates, driven by double-digit growth in oncology and rare disease, with core operating profit up 12% and core EPS up 5%. Management reaffirmed full-year 2026 guidance for mid-to-high single‑digit revenue growth and low double‑digit core EPS growth, supported by a 21% core tax rate and improving operating margins.
The quarter was marked by positive Phase III data for key new molecular entities tozorakimab in COPD and efzimfotase alfa in hypophosphatasia, alongside 14 regulatory approvals in major markets and multiple new submissions, reinforcing AstraZeneca’s late‑stage pipeline strength. Strategic deals, including a $1.2 billion upfront collaboration with CSPC in obesity and type 2 diabetes and new licensing agreements with Jacobio and Pinetree, underscore the company’s push into next‑generation oncology and metabolic therapies, bolstering its long‑term growth outlook toward its 2030 ambition.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £11500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on prescription medicines, with core strengths in oncology, rare diseases, cardiovascular, renal and metabolic conditions, and respiratory and immunology. The company targets high-value, innovative therapies and is actively expanding its pipeline through internal R&D and strategic collaborations in areas such as antibody-drug conjugates and next-generation metabolic drugs.
Average Trading Volume: 2,655,832
Technical Sentiment Signal: Buy
Current Market Cap: £216.7B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.